Serina Therapeutics Secures Up to $20M in Convertible Note for Parkinson's Trial

Serina Therapeutics, Inc.

Unsecured convertible note up to $20M in five tranches tied to clinical milestones; first $5M available by Oct 1, 2025.
Convertible at $5.18/share (9/8 close), 10% annual interest payable quarterly after first year, 5-yr maturity.
Each tranche carries 100% warrant coverage at $5.44/share; warrants expire 60 days after first Cohort 2 dose or Sept 30, 2026.
Proceeds to advance SER-252 Phase 1b registrational trial for advanced Parkinson's under 505(b)(2) NDA path.
IND submission planned Q4 2025; dosing in Australia Q4 2025 and U.S. initiation Q1 2026.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.